Partnership to enhance diabetic patient care

AstraZeneca Pharmaceuticals (Phils.), Inc. has entered into a partnership agreement with Multicare Pharmaceuticals Philippines Inc. for the sale, marketing and distribution of its Saxagliptin and Saxagliptin + Metformin XR brands. The agreement took effect last May 1, which will allow said brands to have a more focused priority promotion and sustained high level of interaction with healthcare professionals.

“We are very excited with this partnership with Multicare because it will enable us to reach more physicians and optimize value that Saxagliptin can bring to Filipino patients afflicted with diabetes. This initiative is a reinforcement to our already strong presence in the diabetes market,” said Lotis Ramin, marketing director, AstraZeneca Philippines.

Diabetes is one of AstraZeneca’s global key priorities and the company is well- positioned given their presence in the newest and fastest growing diabetes classes - DDP-IVi, GLP1 analogue and SGLT2i.

“This collaboration enables us to help even more Filipino patients with a partner who is well-established and has a strong diabetes franchise. Partnering with Multicare, one of the fastest growing companies in the diabetes segment today, supports our vision to reach and assist more patients with Type 2 Diabetes,” Michael Pineda, AstraZeneca Philippines CFO said.

“We are privileged to partner with pharmaceutical leader AstraZeneca in enhancing the health of Filipinos with diabetes,” said Meneleo Hernandez Jr., president, Multicare Pharmaceuticals Philippines Inc. said.

Saxagliptin is a once-daily tablet for the treatment of type 2 diabetes in adults. It is used in combination with diet and exercise to control high blood sugar levels. Saxagliptin belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which stimulate the pancreas to release more insulin after a meal. Saxagliptin and Saxagliptin + Metformin XR are prescription medications and should only be used upon the advice of a doctor.